Skip to main content
Year archive

argenx SE — 2021 filings

All 57 regulatory filings released by argenx SE (1AE) in 2021, sourced directly from the official regulator.

57 Filings
2021 Period
2021 filings (57)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2021-12-22 English
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Regulatory Filings
2021-12-20 English
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement
2021-11-10 English
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
Earnings Release Q3 2021
2021-10-28 English
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
Report Publication Announcement
2021-10-21 English
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
Investor Presentation
2021-10-08 English
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement
2021-09-07 English
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Regulatory Filings
2021-08-25 English
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
Regulatory Filings
2021-08-04 English
FORM S-8
Registration Form
2021-07-29 English
F-3ASR
Regulatory Filings
2021-07-29 English
Interim / Quarterly Report 2021
Interim / Quarterly Report H1 2021
2021-07-29 English
6-K
Foreign Filer Report
2021-07-29 English
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
Interim / Quarterly Report H1 2021
2021-07-29 English
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
Report Publication Announcement
2021-07-22 English
argenx to Host Virtual R&D Day on July 20, 2021
Regulatory Filings
2021-07-14 English
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Earnings Release Q2 2021
2021-06-17 English
FORM 6-K
Foreign Filer Report
2021-06-07 English
argenx to regain global rights to cusatuzumab
Regulatory Filings
2021-06-07 English
FORM 6-K
Foreign Filer Report
2021-06-01 English
argenx Appoints Karl Gubitz as Chief Financial Officer
Board/Management Information
2021-06-01 English
argenx to Present at Upcoming Investor Conferences
Investor Presentation
2021-06-01 English
FORM 6-K
Foreign Filer Report
2021-05-14 English
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
Interim / Quarterly Report Q1 2021
2021-05-14 English
argenx announces results of Annual General Meeting of Shareholders
AGM Information
2021-05-12 English
FORM 6-K
Foreign Filer Report
2021-05-11 English
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
Report Publication Announcement
2021-05-07 English
argenx Management to Present at Upcoming Virtual Investor Conferences
Report Publication Announcement
2021-04-28 English
argenx SE announces 2021 AGM
AGM Information
2021-04-07 English
argenx SE announces 2021 AGM
Annual Report FY 2020
2021-04-07 English
Annual Report 2020
Annual Report FY 2020
2021-04-02 English
argenx announces Annual General Meeting of Shareholders on May 11, 2021
AGM Information
2021-03-31 English
20-F
Annual Report FY 2020
2021-03-30 English
FORM 6-K
Foreign Filer Report
2021-03-30 English
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
Annual Report FY 2020
2021-03-04 English
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
Earnings Release FY 2020
2021-03-04 English
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Regulatory Filings
2021-03-02 English
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
Report Publication Announcement
2021-02-25 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-16 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-10 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-08 English
argenx announces closing of global offering
Capital/Financing Update
2021-02-08 English
FORM 6-K
Foreign Filer Report
2021-02-04 English
424B5
Prospectus
2021-02-04 English
argenx announces full exercise of underwriters’ option to purchase additional ADSs
Share Issue/Capital Change
2021-02-04 English
argenx raises $1.0 billion in gross proceeds in a global offering
Capital/Financing Update
2021-02-03 English
argenx Issues Statement Concerning Efgartigimod
Regulatory Filings
2021-02-03 English
FWP
Regulatory Filings
2021-02-02 English
argenx announces launch of proposed global offering
Capital/Financing Update
2021-02-02 English
424B5
Prospectus
2021-02-01 English
FORM 6-K
Foreign Filer Report
2021-02-01 English
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
Regulatory Filings
2021-02-01 English
FORM 6-K
Foreign Filer Report
2021-01-08 English
argenx Announces 2021 Corporate Priorities
Earnings Release FY 2020
2021-01-08 English
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Regulatory Filings
2021-01-07 English
FORM 6-K
Foreign Filer Report
2021-01-06 English
argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2021-01-04 English